Skip to Content

'
Paul M. Cinciripini, Ph.D.

Present Title & Affiliation

Primary Appointment

Department Chair ad interim, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX
Professor w/Tenure, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX
Director, Tobacco Treatment Program, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Department of Psychiatry, Baylor College of Medicine Psychiatry & Behavioral Sciences, Houston, TX
Adjunct Professor, Department of Behavioral Science, UT School of Public Health, Houston, TX
Adjunct Professor, Department of Psychology, University of Houston, Houston, TX

Bio Statement

 I serve as Professor and Chair ad interim for the Department of Behavioral Science, and I am the Director of the Tobacco Treatment Program at UT MD Anderson Cancer Center. I have over 30 years of experience conducting basic and clinical research in the area of smoking cessation and nicotine psychopharmacology. My major research interests includes studies developing novel behavioral and pharmacological treatments for nicotine dependence, and those that study individual differences associated with treatment outcome. In particular my work in this area has focused on psychological (negative affect, coping self-efficacy ), psychophysiological  (emotional reactivity), neural (EEG/fMRI) and genetic predictors of treatment outcome (pharmacogenetics). In addition to community based samples my work has also involved  populations with psychiatric and medical co-morbidities including depression, pregnancy and cancer. I have authored over 190 articles and book chapters, conducted over 20 NIH- and other-sponsored randomized clinical trials examining behavioral and pharmacological interventions for smoking cessation, and served as a senior co-investigator on over 20 NIH sponsored trials, and mentored 20 junior scientists. I am presently the PI or site PI on five active NIH-funded studies.   I can make a major contribution to this study working with the PI as an senior co-investigator with the experience and infrastructure needed to conduct large scale clinical trials including those focusing on pregnant women and other special populations.

 

 

Research Interests

Paul M. Cinciripini, Ph.D. is Professor and Chair ad interim of the Department of Behavioral Science and Director of the Tobacco Treatment Program at the University of Texas MD Anderson Cancer Center. He has over 30 years of experience conducting basic and clinical research in the area of smoking cessation and nicotine psychopharmacology.   Dr. Cinciripini has been the recipient of several NIH-, extramural- and industry-sponsored research grants and is the author of over 190 articles and book chapters. Dr. Cinciripini’s major research includes studies of nicotine titration and compensation, psychophysiological effects of nicotine during stress, individual differences in the effects of nicotine on EEG and cardiovascular activity, genetic factors treatment outcome, pharmacogenetic effects of antidepressants during smoking cessation, and recent studies using startle probe and EEG/ERP methodology to examine the relations between genetics, emotional reactivity, nicotine exposure and nicotine withdrawal. He has also studied the effects of depression, coping behavior, and self-efficacy as well as genetic factors related to nicotine dependence and tested novel behavioral and pharmacological approaches for treatment. Examples of his work in this latter area include: the development of a “scheduled smoking” procedure and a recent application of this technology for delivery on a handheld computer; development of a smoking cessation video series for pregnant smokers; evaluating combination therapies using nicotine replacement, behavioral counseling, and other approaches; and testing novel pharmacological compounds, including anxiolytics, antidepressants, nicotine partial agonists, and cannabinoid antagonists. He is presently the PI on several NIH-funded clinical trials, including, “Evaluating New Nicotine Standards for Cigarettes  (CENIC),” which addresses the best approach to reducing nicotine in cigarettes by comparing a gradual vs. immediate reduction to low levels of nicotine; and  “Pharmacogenetics of Nicotine Addiction Treatment (PNAT),” which optimizes pharmacotherapeutic choices for individuals who wish to quit smoking. 

Education & Training

Degree-Granting Education

1978 Auburn University, Auburn, AL, PHD, Cum Laude, Clinical Psychology
1976 Auburn University, Auburn, AL, MS, Clinical Psychology
1974 Pennsylvania State University, State College, PA, BS, Psychology

Postgraduate Training

1977-1978 Clinical Residency, Clinical Psychology, Western Psychiatric Institute and Clinic, The University of Pittsburgh School of Medicine, Pittsburgh, PA

Board Certifications

1996 American Psychological Association Division 38
1993 American Board of Professional Psychology
1989 American Board of Behavioral Psychology
1983 Texas State Board of Examiners in Psychology

Experience/Service

Academic Appointments

Associate Professor w/Tenure, Department of Behavioral Science, Division of OVP, Cancer Prevention and Population Sciences, University of Texas M. D. Anderson Cancer Center, Houston, TX, 10/1994-9/2001
Associate Professor w/Tenure, Department of Psychiatry, University of Texas Medical Branch, Galveston, TX, 1988-1994
Assistant Professor, Department of Psychiatry, University of Texas Medical Branch, Galveston, TX, 1983-1988
Assistant Professor, Physiology & Behavioral Science, Minnesota School of Medicine, Duluth, MN, 1978-1983

Institutional Committee Activities

Chair, Search Committee: Section Chief of Behavioral Statistics, 2/2010-9/2012
Member, OVP Capital Equipment - Faculty Ranking Committee, 2/2009-present
Member, American Cancer Society Institutional Research Grant Review Committee, 1/2008-1/2011
Member, Department of Epidemiology Chair Search Committee, 2008-9/2010

Selected Publications

Peer-Reviewed Original Research Articles

1. Lerman C, Schnoll RA, Hawk LW, Cinciripini PM, George TP, Wileyto EP, Swan GE, Benowitz N, Heitjan DF, Tyndale RF, Leone F, Glick HA, Pinto A, Sanborn PM, Gariti P, Landis JR, Novalen M, Aziziyeh A, Mahoney M, Karam-Hage M, Conti DV, Bergen A. A Randomized Placebo-controlled Trial to Test a Genetically-informed Biomarker for Personalizing Treatment for Tobacco Dependence. Lancet. In Press.
2. Parrott, CE, Rathnayaka N, Blalock JA, Minnix JA, Cinciripini PM, Vincent JP, Wetter DW, Green C. Examination of the Wisconsin Inventory of Smoking Dependence Motives (WISDM-68) factor structure in a sample of pregnant smokers. Nicotine Tob Res. In Press.
3. Cui Y, Robinson JD, Engelmann JF, Lam CY, Minnix JA, Karam-Hage M, Wetter DW, Kosten TR, Cinciripini PM. Reinforcement sensitivity underlying treatment-seeking smokers’ affect, smoking reinforcement motives, and affective responses. Psychology of Addictive Behaviors. In Press.
4. Wippold R, Karam-Hage M, Blalock J, Cinciripini PM. Selection of optimal tobacco cessation medication treatment in cancer patients. Clinical Journal of Oncology Nursing. In Press.
5. Robinson JD, Versace F, Engelmann JM, Yong C, Slapin A, Oum R, Cinciripini PM. The Motivational Salience of Cigarette-related Stimuli Among Former, Never, and Current Smokers. Experimental & Clinical Psychopharmacology. In Press.
6. Lin J, Blalock JA, Chen M, Ye Y, Gu J, Cohen L, Cinciripini PM, Wu X. Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. Cancer Epidemiol Biomarkers Prev. e-Pub 11/21/2014. PMID: 25416716.
7. Robinson JD, Engelmann JM, Cui Y, Versace F, Waters AJ, Gilbert DG, Gritz ER, Cinciripini PM. The effects of nicotine dose expectancy and motivationally relevant distracters on vigilance. Psychol Addict Behav 28(3):752-760, 9/2014. e-Pub 5/2014. PMID: 24841184.
8. Stotts AL, Northrup TF, Cinciripini PM, Minnix J, Blalock J, Mullen PD, Pedroza C, Blackwell S. A Randomized, Controlled Pilot Trial of Bupropion for Pregnant Smokers: Challlenges and Future Directions. American J Perinatol. e-Pub 8/2014. PMID: 25111040.
9. Cano MÁ, Lam CY, Chen M, Adams CE, Correa-Fernández V, Stewart DW, McClure JB, Cinciripini PM, Wetter DW. Positive smoking outcome expectancies mediate the association between negative affect and smoking urge among women during a quit attempt. Exp Clin Psychopharmacol 22(4):332-40, 8/2014. e-Pub 5/5/2014. PMCID: PMC4115029.
10. Chenoweth MJ, Novalen M, Hawk LW, Schnoll RA, George TP, Cinciripini PM, Lerman C, Tyndale RF. Known and Novel Sources of Variability in the Nicotine Metabolite Ratio in a Large Sample of Treatment-Seeking Smokers. Cancer Epidemiology and Biomarkers, 7/2014. e-Pub 7/2014. PMID: 25012994.
11. Ostroff JS, Burkhalter JE, Cinciripini PM, Li Y, Shiyko MP, Lam CY, Hay JL, Dhingra LK, Lord-Bessen J, Holland SM, Manna R. Randomized Trial of a Pre-Surgical Scheduled Reduced Smoking Intervention for Patients Newly Diagnosed with Cancer. Health Psychol 33(7):737-747, 7/2014. e-Pub 7/2013. PMCID: PMC4116187.
12. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: An overview for clinicians. CA Cancer J Clin 64(4):272-90, 7/2014. e-Pub 5/9/2014. PMID: 24817674.
13. Adams CE, Chen M, Guo L, Lam CY, Stewart DW, Correa VF, Cano MA, Heppner WL, Vidrine JI, Li Y, Ahluwalia JS, Cinciripini PM, Wetter DW. Mindfulness Predicts Lower Affective Volatility among African Americans During Smoking Cessation. Psychology of Addictive Behaviors 28(2):580-585, 6/2014. e-Pub 6/2014. PMCID: PMC4096677.
14. Versace F, Engelmann JM, Robinson JD, Jackson EF, Green CE, Lam CY, Minnix JA, Karam HM, Brown VL, Wetter DW, Cinciripini PM. Prequit fMRI Responses to Pleasant and Cigarette Cues Predict Smoking Cessation Outcome. Nicotine Tob Res 16(6):697-708, 6/2014. e-Pub 12/2013. PMCID: PMC4015090.
15. Schnoll RA, George T, Hawk L, Cinciripini P, Wileyto P, Tyndale RF. The relationship between nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology 231(12):2515-2523, 6/2014. e-Pub 1/2014. PMCID: PMC4040302.
16. Waters AJ, Szeto EH, Wetter DW, Cinciripini PM, Robinson JD, Li Y. Cognition and Craving During Smoking Cessation: An Ecological Momentary Assessment Study. Nicotine Tob Res 16 Suppl 2:S111-8, 5/2014. e-Pub 7/30/2013. PMCID: PMC3977632.
17. Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Prev Med 62C:60-63, 5/2014. e-Pub 2/8/2014. PMID: 24518006.
18. Lam CY, Businelle MS, Aigner CJ, McClure JB, Cofta-Woerpel L, Cinciripini PM, Wetter DW. Individual and Combined Effects of Multiple High-Risk Triggers on Postcessation Smoking Urge and Lapse. Nicotine Tob Res 16(5):569-575, 5/2014. e-Pub 12/2013. PMCID: PMC3977487.
19. Lam CY, Businelle MS, Cofta-Woerpel L, McClure JB, Cinciripini PM, Wetter DW. Positive smoking outcome expectancies mediate the relation between alcohol consumption and smoking urge among women during a quit attempt. Psychology of Addictive Behaviors 28(1):163-172, 3/2014. e-Pub 3/2014. PMCID: PMC4115029.
20. Kendzor D, Wetter DW, Reitzel LR, Vidrine JI, Mazas C, Cinciripini PM, Lam C, Fernandez VC, Cano M, Businelle M. The Influence of Discrimination on Smoking Cessation among Latinos. Drug and Alcohol Dependence 136:143-148, 3/2014. e-Pub 1/2014. PMCID: PMC3967740.
21. Rabius V, Karam MH, Blalock J, Cinciripini PM. "Meaningful use" provides a meaningful opportunity. Cancer 120(4):464-468, 2/2014. e-Pub 2/2014. PMCID: PMC4054930.
22. Vidrine JI, Businelle MB, Reitzel LR, Cao Y, Cinciripini PM, Marcus MT, Li Y, Wetter DW. Coping Mediates the Association of Mindfulness with Psychological Stress, Affect and Depression Among Smokers Preparing to Quit. Mindfulness. e-Pub 1/2014.

Invited Articles

1. Cinciripini PM, Karam-Hage M. Study suggests varenicline safe and effective among adults with stable depression. Evid Based Med 19(3):92, 6/2014. e-Pub 1/2014. PMID: 24482150.

Abstracts

1. Karam MH, Robinson JD, Sharma M, Blalock J, Rabius V, Cinciripini P. Bupropion XL has the same effectiveness and similar side effect profile as Bupropion Sr when used for Smoking Cessation among Cancer Patients. 2014 Society for Research on Nicotine and Tobacco, Seattle, Washington, 2/2014.
2. Northrup TF, Blackwell SC, Hutchinson MS, Blalock J, Minnix J, Mullen PD, Pedroza C, Mulpur S, Cinciripini P, Stotts AL. Challlenges in Recruitment for a Phase II Trial of Brpropion for Smoking Cessation in Pregnancy. 2014 Society for Research on Nicotine and Tobacco, Seattle, Washington, 2/2014.
3. Rabius V, Cinciripini P. Development and effectiveness of a Multi-layered Tobacco Cessation Program for Cancer Patients. 2014 Society for Research on Nicotine and Tobacco, Seattle, Washington, 2/2014.
4. Blalock JA, Mathew AR, Robinson JD, Brown RA, Karam HM, Cinciripini PM. Evaluation of mediators of an intensive depression-focused intervention for pregnant smokers using mediated moderation analysis. 2014 Society for Research on Nicotine and Tobacco, Seattle, WA, 2/2014.

Book Chapters

1. Karam-Hage M, Cinciripini PM. Tobacco Cessation. In: Advances in Cancer Survivorship Management. MD Anderson Cancer Care Series, First. Ed(s) Buzdar AU, Freeman RS. Springer: New York, 257-274, 2015.
2. Karam-Hage M, Rabius V, Cinciripini PM, Robinson J, Gritz E. Nicotine Dependence: Current Treatments and Future Directions. In: Abeloff's Clinical Oncology, 5th. Ed(s) Niederhuber J, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Elsevier: Philadelphia, 360-371, 2014.

Grant & Contract Support

Title: Smoking, Emotional Reactivity and Stress, TBD
Funding Source: NIH/NCI
Role: Principal Investigator
Duration:
 
Title: Evaluating New Nicotine Standards for Cigarettes - CENIC Project 2, TBD
Funding Source: NIH/NIDA
Role: Principal Investigator-MDACC
Principal Investigator: Eric Donny
Duration: 9/1/2014 - 8/31/2017
 
Title: Intrinsic Reward Sensitivity & Smoking Cessation with Varenicline or Patch NRT, TBD
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 9/1/2014 - 8/30/2017
 
Title: Promoting Informed Decisions about Lung Cancer Screening, TBD
Funding Source: Patient-Centered Outcomes Research Institute
Role: Co-Investigator
Principal Investigator: Robert Volk
Duration: 5/1/2014 - 4/30/2017
 
Title: Smartphone delivered attentional bias modification training for smokers, TBD
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Jason Robinson
Duration: 4/1/2014 - 3/31/2018
 
Title: Neurobiological substrates of imminent smoking: A missing link in cue reactivity, TBD
Funding Source: NIH/NIDA
Role: Mentor
Duration: 7/1/2013 - 6/30/2018
 
Title: Using Deep Sequencing Technology to Study Genes & Behavioral Phenotypes Related to Smoking Cessation, Negative affect & Nicotine Withdrawal, TBD
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 6/1/2013 - 5/31/2016
 
Title: A Phase 4, non-treatment, follow-up for cardiac assessments following use of smoking cessation treatments in subjects with and without a history of psychiatric disorders, cardiac assessments after treatment, TBD
Funding Source: Pfizer Inc.
Role: Principal Investigator
Duration: 3/22/2013 - 3/21/2015
 
Title: Extended depression-focused smoking cessation treatment in the postpartum period, Grant
Funding Source: NIH
Role: Co-Investigator
Principal Investigator: Jan Blalock
Duration: 9/1/2012 - 8/31/2017
 
Title: Extended depression-focused smoking cessation treatment in the postpartum period, Grant
Funding Source: NIH
Role: Co-Investigator
Principal Investigator: Janice Blalock
Duration: 9/1/2012 - 8/31/2017
 
Title: Identifying topiramates therapeutic mechanisms through motivational salience, Grant
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Jason Robinson
Duration: 9/1/2012 - 8/31/2017
 
Title: The Generalizability of Attentional Bias Modification in Smokers, Grant
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Jason Robinson
Duration: 9/1/2012 - 8/31/2016
 
Title: The Generalizability of Attentional Bias Modification in Smokers, Grant
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Jason Robinson
Duration: 9/1/2012 - 8/31/2016
 
Title: Beyond Cue Reactivity: ERPs, Sensitivity to Natural Rewards and Smoking Cessation, Grant
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Francesco Versace
Duration: 7/15/2012 - 6/30/2015
 
Title: Sensitivity to natural rewards and nicotine addiction, Grant
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Francesco Versace
Duration: 4/1/2012 - 3/31/2016
 
Title: Genetic and Environmental Determinants of Quitting Smoking, Grant
Funding Source: NIH/NHLBI
Role: Co-Principal Investigator
Duration: 4/1/2012 - 3/31/2016
 
Title: A Phase 4, randomized, double-blind, active and placebo-controlled, multicenter study evaluating the neuropsychiatric safety and efficacy of 12 weeks varenicline tartrate 1mg BID for smoking cessation in subjects with and without a history of psychiatric disorder, Grant
Funding Source: Pfizer Inc.
Role: Principal Investigator-MDACC
Duration: 8/16/2011 - 8/15/2015
 
Title: Pharmacogenetics of Nicotine Addiction Treatment (PNAT)., Grant
Funding Source: NIH/NIDA
Role: Principal Investigator-MDACC
Principal Investigator: Lerman, Caryn (PI) (Cinciripini, Site PI)
Duration: 8/1/2010 - 6/30/2015
 
Title: Role of Habenula in Tobacco Addiction, Grant
Funding Source: NIH/NIDA
Role: Mentor
Duration: 8/1/2010 - 12/31/2014
 
Title: New pharmacotherapy for alcohol and co-morbid disorders, Grant
Funding Source: NIH/NIAAA
Role: Co-Principal Investigator
Principal Investigator: Cinciripini, P., Alt-Daoud, N., Anthenelli, R.
Duration: 7/1/2010 - 6/30/2015
 
Title: Neurobehavioral metrics for the assessment and treatment of depression, Grant
Funding Source: NIH/NIMH
Role: Co-Investigator
Principal Investigator: Chiu
Duration: 7/1/2010 - 1/31/2015
 
Title: Suppression of Negative Affect Indexed by the Late Positive Potential in Smokers, Grant
Funding Source: NIH/NIDA
Role: Co-Investigator
Principal Investigator: Minnix, Jennifer
Duration: 5/1/2009 - 4/30/2015
 
Title: Combating Tobacco in the United States Army , Grant
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Prokhorov
Duration: 4/1/2009 - 4/30/2015
 
Title: Effectiveness of Varenicline plus Bupropion for Smoking Cessation, Grant
Funding Source: NIH/NIDA
Role: Principal Investigator
Duration: 4/1/2009 - 12/31/2014
 
Title: Ecological Momentary Assessment, Peak-end Rule, and Smoking Relapse., Grant
Funding Source: American Cancer Society (ACS)
Role: Mentor
Principal Investigator: Lam, Cho
Duration: 1/1/2009 - 12/31/2014

Last updated: 11/26/2014